In September 2011, CardioKinetix closed a two tranche round of series E financing worth $44m, led by venture capital (VC) firms SV Life Sciences and New Leaf Venture Partners.
CardioKinetix, a US-based medical device company backed by merchant banks, has extended its series E round by $4m from venture capital firm Panorama Capital.
In September 2011, CardioKinetix closed a two tranche round of series E financing worth $44m, led by venture capital (VC) firms SV Life Sciences and New Leaf Venture Partners.
Further participation came from financial services firm JP Morgan’s corporate venturing unit, JP Morgan Partners, and H&Q Healthcare Investors, the corporate venturing division of investment adviser Hambrecht…
